CDNF in patients
Our CDNF is a novel drug candidate that has the potential to stop the progression of Parkinson’s disease by protecting neurons from degeneration and restoring the functions of already damaged neurons. CDNF is currently in Phase 1-2 randomized, placebo-controlled, double-blind, multicenter clinical study in three university hospitals in Sweden and Finland for the treatment of Parkinson’s disease. The patient recruitment has been closed in the ongoing Phase 1-2 clinical study. More information about the clinical study is available at treater.eu. Any concrete plans for further clinical studies will be announced on our web site.
Parkinson’s disease is an incurable, progressive brain disorder estimated to affect over seven million patients worldwide. It is caused by the degeneration of dopamine-producing neurons in the brain. The full mechanism behind the degeneration is not fully understood yet. It is however known that the accumulation and aggregation of alpha-synuclein in those neurons is at the core of the disease, and that the neuronal degeneration is associated with a cell level phenomenon called ER stress. The typical symptoms of the disease include tremors, slowness of movement, muscle stiffness, and impaired balance. As the disease progresses, other possible symptoms include sleep problems, depression, speech changes, and severe constipation.
The drug candidate CDNF is a natural human protein, which has been shown to protect neurons, and help degenerating neurons restore their functionality. This is based on several mechanisms, including alleviation of ER stress and reduction of alpha-synuclein aggregation. Both are highly relevant to Parkinson’s disease.
In Parkinson’s disease models, CDNF restores the function of already damaged neurons and protects healthy neurons from degeneration. Based on this, CDNF has the potential to alleviate both motor and non-motor symptoms of Parkinson’s disease as well as stop the further progression of the condition. For more detailed information on the mechanism of action of CDNF, please see here.
CDNF is administered directly in the affected area in the brain with a sophisticated drug delivery device that is implanted in a neurosurgical procedure comparable to the placement of a Deep Brain Stimulation device.
Introductory video on CDNF
CDNF in media
EU success story article about CDNF: Novel drug delivered direct to brain may halt Parkinson’s